Mesoblast (MSB)

Business description

Mesoblast is developing adult stem cell therapies based on its proprietary MPC and culture-expanded MSC platforms. It has six late-stage clinical trials across four areas.

Stock data

Market cap.A$556.8m
Last closeA$1.46
High / Low (52 weeks)A$3.6 / A$1.0
Stock market listingAU
Forecast net cash (US$m)79.4
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual28.6(28.8)(54.9)
Relative *27.0(32.1)(58.3)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Achillion Pharmaceuticals Acorda Therapeutics
Actinium Pharmaceuticals Active Biotech
Acucela Addex Therapeutics
Adherium Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
AFT Pharmaceuticals Agennix
Akari Therapeutics Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
Astex Pharmaceuticals Athersys
Atossa Genetics Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
Bone Therapeutics BrainStorm Cell Therapeutics
BTG C4X Discovery Holdings
Can-Fite BioPharma Capstone Therapeutics
Carmat Cell Therapy
Celldex Therapeutics Cellectis
Celyad Cerulean Pharma
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel co.don AG
Consort Medical Corium International
Crossject Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics Egalet Corporation
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Forward Pharma
Futura Medical Galapagos
Galmed Pharmaceuticals Genedrive
Genfit Genmab
Genticel GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings ImmuPharma
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
International Stem Cell Corporation Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Lifewatch AG Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals MethylGene
Midatech Pharma Molecular Partners
MolMed Mologen AG
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Nektar Therapeutics NeoStem
Neovacs NetScientific
Newron Pharmaceuticals Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Oryzon Genomics Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
PDL BioPharma Pharmacyclics
PharmaMar Pharmaxis
Pharming Group Photocure
Phylogica Pixium Vision
Prescient Therapeutics Prima BioMed
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Quantum Pharmaceuticals
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Silence Therapeutics
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals TearLab Corp
Tekmira TESARO
Theraclion Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Group Tissue Therapies
Titan Pharmaceuticals Tonix Pharmaceuticals
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
TruScreen Ltd TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Wilex
Xencor Zafgen
Zealand Pharma Ziopharm Oncology

Company news

Mesoblast Limited (NASDAQ:MESO) Updated Price Targets

Tue, 23 Aug 2016 07:40:43 GMT

Mesoblast Ltd. (MESO) to Release Earnings on Wednesday

Tue, 23 Aug 2016 11:03:45 GMT

Mesoblast limited moves to reassure investors

Mon, 04 Jul 2016 04:41:15 GMT

There could be more pain ahead for Mesoblast limited as credibility sinks

Tue, 14 Jun 2016 01:06:26 GMT

Mesoblast limited trading halt leaves investors guessing

Fri, 03 Jun 2016 01:52:30 GMT

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2014A 25.1 (83.9) (75.5) (23.64) N/A N/A
2015A 32.4 (98.0) (94.9) (29.59) N/A N/A
2016E 44.1 (54.1) (53.5) (13.84) N/A N/A
2017E 7.1 (78.8) (78.8) (20.67) N/A N/A

Last updated on 18/07/2016

Investment summary

Mesoblast announced impressive early results from the first cohort of its Phase II trial of MPC therapy in RA patients refractory to biologics. The data are comparable to response rates seen with TNF alpha-biologics in first-line therapy and better than approved JAK inhibitor Xeljanz in comparable biologic refractory patients. JCR-031 was launched in Japan for acute graft versus host disease (GvHD) in February, following approval in September 2015. Clinical data from two phase III studies of MPC-150-IM in heart failure will support regulatory approval; the first trial cleared an interim safety analysis in Q216. Mesoblast has regained full rights to the cardiovascular program from Teva and at the appropriate time will seek to partner with a pharma company with a cardiovascular focus. Teva and Mesoblast continue to collaborate in CNS and bone marrow transplant fields. Mesoblast had cash of cUS$80M on 30 June. It has entered an equity finance facility with Kentgrove Capital to fund the ongoing Phase III CHF trial and a 600-patient confirmatory trial.

Last updated on 02/08/2016

Industry outlook

Mesoblast is the leading mesenchymal stem cell development company, with two platforms (MPCs, MSCs) and nine clinical candidates in Phase II and III. Alliances with JCR, Lonza and Teva underpin the key programmes.

Last updated on 02/08/2016

Key management

Company address

Level 39
55 Collins Street
Melbourne 3000
Australia
+61 3 9639 6036
View website